ALKS241115C18000
- 0.00
- 0.000.00%
Alkermes Newsroom
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt
Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive Buy Rating
Alkermes (ALKS) Gets a Hold From J.P. Morgan
Alkermes Is Maintained at Neutral by JP Morgan
Alkermes: Balancing Near-Term Challenges With Long-Term Orexin Market Potential Justifies Hold Rating
Cantor Fitzgerald Maintains Alkermes(ALKS.US) With Buy Rating, Cuts Target Price to $43
H.C. Wainwright Maintains Alkermes(ALKS.US) With Hold Rating, Maintains Target Price $37
BofA Securities Maintains Alkermes(ALKS.US) With Hold Rating
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $30 to $43
Alkermes (ALKS) Receives a New Rating From Cantor Fitzgerald
Express News | HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $37 Price Target
Alkermes Analyst Ratings
Alkermes Price Target Lowered to $30 From $32 at Goldman Sachs
Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)
Alkermes Plc (ALKS) Q3 2024 Earnings Call Transcript Summary
Alkermes Plc (ALKS) Q3 2024 Earnings Call Transcript
Alkermes: Promising Orexin Developments and Strong Revenue Guidance Support Buy Rating
Alkermes | 10-Q: Q3 2024 Earnings Report
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday